T-Cube[®] Multi-Drug Oral Fluid Test Cube

For in vitro diagnostic use.

T-Cube® One Step Oral Fluid Drug Test offers qualitative detection of the following drugs of abuse and their principal metabolites in human oral fluid at specified cut-off levels for use in employment and insurance testing: Amphetamine (AMP), Barbiturates (BAR), Cocaine (COC), Marijuana (THC), Methadone (MTD), Methamphetamine (MET), Methylenedioxymethamphetamine (MDMA), Opiate (OPI), Oxycodone (OXY) and Phencyclidine (PCP).

INTENDED USE

T-Cube[®] One Step Oral Fluid Drug Test is a rapid oral fluid screening test. The test is a lateral flow, one-step immunoassay for the qualitative detection of specific drugs and their metabolites in human oral fluid at the following cut off concentrations for use in employment and insurance testing.

Test	Calibrator	Cut off (ng/mL)
Amphetamine (AMP)	D-Amphetamine	50
Barbiturates (BAR)	Secobarbital	20
Cocaine (COC)	Cocaine	20
Marijuana (THC)	Δ9- THC	40
Methadone (MTD)	Methadone	30
Methamphetamine (MET)	D-Methamphetamine	50
Methylenedioxymethampheta mine (MDMA)	3,4- Methylenedioxymethamphe taminel	50
Opiate (OPI)	Morphine	40
Oxycodone (OXY)	Oxycodone	20
Phencyclidine (PCP)	Phencyclidine	10

This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert.

Amphetamine (AMP): Amphetamine is a sympathomimetic amine with therapeutic indications. The drug is often self-administered by nasal inhalation or oral ingestion.

Barbiturates (BAR): Barbiturates are a class of central nervous system depressants. Abuse of barbiturates can lead not only to impaired motor coordination and mental disorder, but also to respiratory collapse, coma and even death. Barbiturates are taken orally, rectally, or by intravenous and intramuscular injections.

Cocaine (COC): Cocaine derived from leaves of coca plant, is a potent central nervous system stimulant and a local anesthetic. Among the psychological effects induced by using. Cocaine are euphoria, confidence and a sense of increased energy, accompanied by increased heart rate, dilation of the pupils, fever, tremors and sweating.

Marijuana (THC): Tetrahydrocannabinol, the active ingredient in the marijuana plant (cannabis sativa), is detectable in oral fluid shortly after use. The detection of the drug is thought to be primarily due to the direct exposure of the drug to the mouth (oral and smoking administrations) and the subsequent sequestering of the drug in the buccal cavity. Methadone (MTD): Methadone is a synthetic analgesic drug that is originally used in the treatment of narcotic addict. The drug is often administered orally or intravenously and is metabolized in the liver and excreted in urine.

Methamphetamine (MET): Methamphetamine is a potent stimulant chemically related to amphetamine but with greater CNS stimulation properties. The drug is often self-administered by nasal inhalation, smoking or oral ingestion.

Methylenedioxymethamphetamine(MDMA): Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity. Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users.

Opiates (OPI): The opiates such as heroin, morphine, and codeine are derived from the resin of opium poppy. The principal metabolites of opiates are morphine, morphine-3-glucuroride, normorphine and codeine with a half-life of about 3 hours. Heroin is quickly metabolized to morphine. Thus, morphine and morphine glucuronide might both be found in the saliva of a person who has taken only heroin. The body also changes codeine to morphine. Thus, the presence of morphine (or the metabolite, morphine glucuronide) in the saliva indicates heroin, morphine and/or codeine use. The window of detection varies for different opiates. Codeine can be detected within one hour and up to 7-21 hours after a single oral dose. Morphine is detectable for several days after a dose.

Oxycodone (OXY): Oxycodone is known as Oxycontin, Roxicodone and is an ingredient of Percodan, Percocet, Roxicet and Tylox. Oxycodone is a semi-synthetic opiates derived from opium. Like other opiates, oxycodone is characterized by its analgesic properties, and the tendency for users to form a physical dependency and develop tolerance with extended use. Oxycodone is usually administered in combination with non-opiate analgesics such as acetaminophen and salicylates for the relief of moderate to severe pain. Oxycodone is a central nervous system depressant that may cause drowsiness, dizziness, lethargy, weakness and confusion. Toxicity in an overdose of oxycodone can lead to stupor, coma, muscle flaccidity, severe respiratory depression, hypotension, and cardiac arrest. Phencyclidine (PCP): Phencyclidine is an arylcyclohexylamine that was originally used as an anesthetic agent and a veterinary tranquilizer. Phencyclidine can produce hallucinations, lethargy, disorientation, loss of coordination, trance-like ecstatic states, a sense of euphoria and visual distortions. It has many street names, such as "angel dust" and "crystal cyclone," etc. Phencyclidine can be administered orally, by nasal ingestion, smoking, or by intravenous injection.

The assay provides a qualitative, preliminary test result. A more specific analytical method must be used in order to obtain a confirmed result. Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS-MS) are preferred confirmatory methods. Professional judgment should be applied to any drug test result, particularly when preliminary results are positive.

PRINCIPLE

T-Cube[®] One Step Oral Fluid Drug Test is a competitive immunoassay that is used to screen for the presence of drugs in oral fluid. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample competitively combine to a limited number of antibody-dye conjugate binding sites.

When the sponge end of the collector is immersed into the oral fluid sample, the sample is absorbed into the device by capillary action, mixes with the antibody-dye conjugate, and flows across the pre-coated membrane. When sample drug levels are zero or below the target cutoff (the detection sensitivity of the test), antibody-dye conjugate binds to the drug/protein conjugate immobilized in the Test Region (T) of the device. This produces a colored band that, regardless of its intensity, indicates a negative result.

When sample drug levels are at or above the target cutoff, the free drug in the sample binds to the antibody-dye conjugate preventing the antibody-dye conjugate from binding to the drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a potentially positive result.

To serve as a procedure control, a colored band will appear at the Control Region (C), if the test has been performed properly.

PRECAUTIONS

Not to be used for clinical diagnosis.
 Do not swallow.
 Discard after first use. The test cannot be used more than once.
 Do not use the test kit beyond expiration date.
 Do not use the test if the pouch is punctured or not sealed.
 Keep out of the reach of children.
 Do not read results after 5 minutes.

8. The used collector and cube should be discarded according to local regulations.

MATERIAL

Materials Provided

• 25 Test Cubes	25 Sponge Collectors
• 5 Additional Sponge Collectors	• One (1) Package Insert

Material Required but Not Provided

STORAGE AND STABILITY

Timer

Store at 4°C - 30°C (39°F - 86°F) in the sealed pouch up to the expiration date
 Keep away from direct sunlight, moisture and heat.
 DO NOT FREEZE.
 Preferably open the pouch only shortly before collection and testing.

SPECIMEN COLLECTION AND PREPARATION


Collect the oral fluid sample using the sponge collector provided. Instruct the donor to not place anything in the mouth including food, drink, gum, or tobacco products for at least 10 minutes prior to collection. No other collection devices should be used with this assay. Oral fluid collected at any time of the day may be used.

TEST PROCEDURE

Allow the kit and specimen to come to room temperature (65°F-86°F/18°C-30°C) prior to testing. AVOID PLACING ANYTHING IN THE MOUTH 10 MINUTES PRIOR TO TESTING.
1. Remove the test cube and the sponge collector from the foil pouch by tearing at the notch. Place the test cube upright on a level surface.

- 2. Put the sponge end of the collector on your tongue or near cheek to collect oral fluid for about 3 minutes until color on saturation indicator strip appears RED in the indicator window. If color on saturation indicator has not turned red at 7 minutes, repeat the collection using one additional sponge collector provided, beginning with Step 1.
- 3. Open the test cube and place the saturated oral fluid collector inside the test cube. Press the sponge collector down firmly until it reaches the bottom of the test cube then tightly close the cube lid. Keep test cube upright on flat surface and follow Step 4.
- 4. Interpreting Drug Test Results:

Read results at 5 minutes. Do not read after 5 minutes.



INTERPRETATION OF RESULTS

Negative (-)

A colored band is visible in the Control Region (C) and the appropriate Test Region (T). It indicates that the concentration of the corresponding drug of that specific test zone is zero or below the detection limit of the test.


Preliminary Positive (+)

A colored band is visible in the Control Region (C). No color band appears in the appropriate test region. It indicates a positive result for the corresponding drug of that specific Test Region (T).

Invalid

If a colored band is not visible in the Control Region (C), the test is invalid. Another test should be run to re-evaluate the specimen. If test still fails, please contact the distributor with the lot number.

Note: There is no meaning attributed to line color intensity or width.



OUALITY CONTROL

Though there is an internal procedural control line in the test device of Control Region (C), the use of external controls is strongly recommended as good laboratory testing practice to confirm the test procedure and to verify proper test performance. Positive and negative control should give the expected results. When testing the positive and negative control, the same assay procedure should be adopted.

LIMITATIONS OF PROCEDURE

- 1. The test provides only a qualitative, preliminary result. A secondary analytical method must be used to obtain a confirmed result. Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS-MS) are preferred confirmatory methods.
- 2. A positive test result does not indicate the concentration of drug in the specimen or the route of administration.
- 3. A negative result may not necessarily indicate a drug-free specimen. Drug may be present in the specimen below the cutoff level of the assay.

PERFORMANCE CHARACTERISTICS

A. Analytical Sensitivity

Standard drugs were spiked into negative PBS pool to the concentration of 0% Cut-off, -50% Cut-off, -25% Cut-off, Cut-off, +25% Cut-off and +50% Cut-off. The results were summarized below.

Drug Conc.	N	AM	1P	BAR		COC		THC		MTD	
(Cut-off Range)	IN	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	30	28	2	25	5	25	5	14	16	25	5
Cut-off	30	12	18	10	20	10	20	14	16	12	18
+25% Cut-off	30	8	22	6	24	6	24	5	25	6	24
+50% Cut-off	30	0	30	0	30	0	30	0	30	0	30

Drug Conc.	Ν	MET MDMA OPI		OXY		PCP					
(Cut-off Range)	IN	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	30	28	2	25	5	14	16	14	16	26	4
Cut-off	30	10	20	10	20	10	20	14	16	14	16
+25% Cut-off	30	8	22	6	24	5	25	5	25	5	25
+50% Cut-off	30	0	30	0	30	0	30	0	30	0	30

B. Analytical Specificity

C. Cross-Reactivity

The following table lists the concentration of compounds (ng/mL) above which T-Cube®

One Step Oral Fluid Drug Test identified positive results at the read time of 5 minutes.

	nuclianca pr		5	Aminopyrine
				Aminopyrine Amoxicillin
Amphetamine (AMP)		Methamphetamine (MET)		
D-Amphetamine	50	D-Methamphetamine	50	Ampicillin
D,L-Amphetamine	125	Fenfluramine	10,000	Ascorbic Acid
β-Phenylethylamine	4,000	p-Hydroxymethamphetamine	400	Apomorphine
Tryptamine	1,500	Methoxyphenamine	25,000	Aspartame
p-Hydroxyamphetamine	800	3,4-	500	Atropine
		Methylenedioxymethampheta		Benzilic Acid
		mine		Benzoic Acid
(+)3,4-	2,500	L-Phenylephrine	4,000	Benzphetamine
Methylenedioxyamphetami ne (MDA)				D,L-Brompheniramine
Methamphetamine	11,000	Procaine	2,000	Caffeine
3,4-	100,000	(1R,2S) - (-) Ephedrine	400	Chloralhydrate
Methylenedioxymethamph	100,000	(1R,23) - (-) Epheunne	400	Chloramphenicol
etamine				Chlorothiazide
Dopamine hydrochloride	8.000			(±) Chlorpheniramine
Dopumine nyuroenionue	0,000	Methylenedioxymethamp		Chlorpromazine
		hetamine (MDMA)		Chloroquine
Barbiturates (BAR)		3.4-	50	Cholesterol
		Methylenedioxymethampheta		Clonidine
		mine		Cortisone
Secobarbital	20	3,4-	300	(-) Cotinine
		Methylenedioxyamphetamine		Creatinine
		HCI		Deoxycorticosterone
Amobarbital	30	3,4-	60	Dextromethorphan
		Methylenedioxyethylampheta		Diclofenac
		mine		Diflunisal
Alphenol	15			Diqoxin
Aprobarbital	20	Opiate (OPI)	40	5
Butabarbital	10	Morphine	40	Diphenhydramine
Butathal	10	Codeine	100	(-)-Ephedrine
Butalbital	250 60	Ethyl morphine	100	β-Estradiol
Cyclopentobarbital		Hydromorphone	1,000	Ethyl-p-aminobenzoat
Pentobarbital Phenobarbital	30 10	Hydrocodone	2,000 400	Fenoprofen
Phenobarbitai	10	Levorphanol Morphine 3-β-D-Glucuronide	50	Furosemide
Cocaine (COC)		Norcodeine	1,500	Gentisic Acid
Cocaine (COC)	20	Normorphine	1,500	Hemoglobin
Benzoylecgonine	100	Nalorphine	10,000	Hydralazine
Cocaethylene	25	Oxycodone	>300,000	Hydrochlorothiazide
Ecqonine	40,000	Oxymorphone	25,000	Hydrocortisone
Ecgonine methylester	12,500	Thebaine	1,500	O-Hydroxyhippuric Ac
Legonine metrylester	12,500	Thebaine	1,500	p-Hydroxytyramine
Marijuana (THC)		Oxycodone (OXY)		Ibuprofen
11-nor- △ 9-THC-9-COOH	25	Oxycodone	20	Iproniazid
11-nor- △ 8-THC-9-COOH	60	Dihydrocodeine	4,000	Isoproterenol
11-hydroxy- △ 9-THC	2,500	Codeine	10,000	Isoxsuprine
△ 8- THC	7,500	Hydromorphone	300,000	Ketamine
△ 9- THC	40	Morphine	11.000	
Cannabinol	1,000	Acetylmorphine	>100,000	
Cannabidiol	10,000	Buprenorphine	>100,000	
		Ethyl morphine	>100,000	BIBLIOGRAPHY OF
Methadone (MTD)				
Methadone	30	Phencyclidine (PCP)		
Doxylamine	5,000	Phencyclidine	10	1. Moolchan, E., et al
		4-Hydroxyphencyclidine	12,500	
			. ,,	Disposition and Ph

A study was conducted to determine the cross-reactivity of the test with compounds spiked

into drug-free PBS stock. The following components show no cross-reactivity when tested

with T-Cube® One Step Oral Fluid Drug Test at a concentration up to 100 µg/mL.

Ketoprofen Loperamide N-Acetylprocainamide Maprotiline Meprobamate Labetalol Meperidine Meprobamate Methylphenidate Nalidixic Acid Naloxone Naltrexone Naproxen Niacinamide Nifedipine D,L-Brompheniramine Norethindrone D-Norpropoxyphene Noscapine D,L-Octopamine Oxalic Acid (±) Chlorpheniramine Oxolinic Acid Oxymetazoline Papaverine Penicillin-G Pentazocine Perphenazine Phenelzine D,L-Propranolol D-Propoxyphene D-Pseudoephedrine Quinidine Ouinine Ranitidine Salicylic acid Serotonin (5-Hydroxytyramine) Sulfamethazine Ethyl-p-aminobenzoate Sulindac Tetracycline Tetrahydrocortisone, 3 Acetate Thiamine Thioridazine D, L-Tyrosine Tolbutamide Triamterene O-Hydroxyhippuric Acid Trifluoperazine Trimethoprim D, L-Tryptophan Tyramine Uric Acid

Acetaminophen

Acetophenetidin

Acetylsalicylic Acid

BIBLIOGRAPHY OF SUGGESTED READING

1. Moolchan, E., et al, "Saliva and Plasma Testing for Drugs of Abuse: Comparison of the Disposition and Pharmacological Effects of Cocaine", Addiction Research Center, IRP, NIDA, NIH, Baltimore, MD. As presented at the SOFT-TIAFT meeting October 1998. 2. Kim, I, et al, "Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration", Clin Chem, 2002 Sept.; 48 (9), pp 1486-96. 3. Schramm, W. et al, "Drugs of Abuse in Saliva: A Review," J Anal Tox, 1992 Jan-Feb; 16

Verapamil


Zomepirac

(1), pp 1-9.

4. McCarron, MM, et al, "Detection of Phencyclidine Usage by Radioimmunoassay of Saliva,"

J Anal Tox. 1984 Sep-Oct.; 8 (5), pp 197-201.

INDEX OF SYMBOLS



Manufactured by Guangzhou Wondfo Biotech Co., LTD Guangzhou, Guangdong, P.R. China 510663

Made in China

Rev. A3 Rel.: 2019/12/05